In recent decades, immune checkpoint inhibitors (ICIs) and anti-programmed cell death 1 (PD1) antibodies (Abs) have been recognized as anchor drugs for the treatment of advanced melanoma, with or without additional drugs such as anti-CTLA-4 Abs in combination [1,2]. Here, PDCD1 is linked to melanoma.